Photo taken from Kefah Mokbel/LinkedIn
Apr 28, 2024, 23:57
Kefah Mokbel summarizes estrogen-alone use and breast cancer incidence by Rowan T. Chlebowski et al
Kefah Mokbel, Chair of The Multidisciplinary Breast Cancer Program at London Breast Institute, shared on LinkedIn:
“Estrogen-only HRT reduces breast cancer risk and women who had prior hysterectomy:
The biological rationale and the totality of the randomized clinical trial evidence supports a conclusion that use of estrogen-alone, among post-menopausal women with prior hysterectomy, significantly reduces breast cancer incidence with findings perhaps not limited to CEE-alone.
Regarding potential biological mechanisms, I propose the following:
- Estrogen promotes apoptosis in breast cells, particularly following short-term estrogen deprivation.
- Estrogen prompts breast cancer cells to enter dormancy after a period of estrogen deprivation.
- Hysterectomy may contribute through decreased levels of anti-Müllerian hormone (AMH) and inhibin B, and increased levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH).
- Estrogen reduces the size of the human breast stem cell pool.”
Additional information.
Source: Kefah Mokbel/LinkedIn
Aaron K. Aragaki
anti-Müllerian hormone (AMH)
Breast Cancer
cancer
Dorothy Lane
follicle-stimulating hormone (FSH)
HRT
hysterectomy
Jean Wactawski-Wende
JoAnn E. Manson
Joanne E. Mortimer
Karen C. Johnson
Kathy Pan
Kefah Mokbel
London Breast Institute
luteinizing hormone (LH)
menopausal women
Meryl S. LeBoff
OncoDaily
Oncology
Rebecca A. Nelson
Rowan T. Chlebowski
Sayeh Lavasani
The Multidisciplinary Breast Cancer Program
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46